Hims 'able to move extremely quickly' if FDA greenlights six wellness peptides, CEO says

Hims & Hers posts $753M in Q2 revenue as it preps for push into peptide market

Hims & Hers posted $753M Q2 revenue (+38% YoY) and acquired a U.S. peptide facility to launch approved peptides by year-end. The $2.2-3.3B peptide market diversifies compounding revenue, but Q2's $86M loss versus $43M YoY profit signals integration drag and runway pressure.